Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1244577

Nc1cccc(Nc2cc(-c3cccc4c3oc3ccccc34)ncn2)c1.O=C(O)C(F)(F)F

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
TSHR P16473 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP2C19 P33261 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
ABL1 P00519 2/20 0.40
BCR P11274 2/20 0.40
TP53 P04637 2/20 0.39
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
POLB P06746 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
CCNT1 O60563 10/20 0.39
CDK9 P50750 10/20 0.39
EGFR P00533 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL1243690 0.92 CYP1A2 (0.41) ALDH1A1TSHRCYP1A2CYP3A4CYP2D6
Trifluoroacetic Acid SCHEMBL1242168 0.91 PIP4K2C (0.45) CCNT1CDK9EGFRPIP4K2C
Trifluoroacetic Acid SCHEMBL1244552 0.88 PTGS1 (0.43) MAPK1ABL1BCRMAPTCCNT1
Trifluoroacetic Acid SCHEMBL1242021 0.88 PIP4K2C (0.49) ALDH1A1ABL1BCRTP53MAPT
SCHEMBL1242170 0.87 ABL1 (0.36) ALDH1A1TSHRCYP1A2CYP3A4CYP2D6
Trifluoroacetic Acid SCHEMBL1243553 0.87 PTGS1 (0.42) ALDH1A1TSHRCYP1A2CYP3A4CYP2D6
Trifluoroacetic Acid SCHEMBL4376788 0.86 ABL1 (0.48) ALDH1A1TSHRCYP1A2CYP3A4CYP2D6
Trifluoroacetic Acid SCHEMBL5611096 0.85 ABL1 (0.38) ALDH1A1TSHRCYP1A2CYP3A4CYP2D6
SCHEMBL1243847 0.84 PIP4K2C (0.49) ALDH1A1MAPTMEN1NPC1POLB
Trifluoroacetic Acid SCHEMBL1242107 0.84 PTGS1 (0.40) ALDH1A1TSHRCYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7879853-B2 tyrosisne kinase inhibitors such as N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-morpholin-4-yl-benzamide, used as anticasrcinogenic or antoproliferative agents, especially in the treatment of breast cancer BAYER SCHERING PHARMA AG (DE) 2011-02-01 US disclosed
EP-1763526-B1 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS BAYER SCHERING PHARMA AG (DE) 2009-06-24 EP disclosed
US-20070208034-A1 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors ATLANTA PHARMA AG (DE) 2007-09-06 US disclosed
EP-1763526-A1 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS Altana Pharma AG (DE) 2007-03-21 EP disclosed
WO-2006000589-A1 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS ALTANA PHARMA AG (DE) 2006-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208034-A1 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors CDK2, DCK, DTYMK ALDH1A1 2113/4885TSHR 4039/4885CYP1A2 2241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.